Article Text

Download PDFPDF
In search of the elusive biomarker(s): a proteomics analysis in rheumatoid arthritis-associated interstitial lung disease
  1. Scott M Matson1,
  2. Joyce S Lee2
  1. 1 Medicine: Pulmonary and Critical Care, University of Kansas School of Medicine, Kansas City, Kansas, USA
  2. 2 Department of Medicine, University of Colorado, Denver, Colorado, USA
  1. Correspondence to Dr Joyce S Lee, Department of Medicine, University of Colorado, Denver, CO 80045, USA; JOYCE.LEE{at}CUANSCHUTZ.EDU

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The development of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) leads to significant morbidity and mortality.1 ILD impacts approximately 10% of patients with RA and even higher percentages have subclinical ILD.2 3 Despite the clinical impact of ILD in a patient with RA, this comorbidity is poorly understood.

Recently, we and others have leveraged our understanding of idiopathic pulmonary fibrosis (IPF) to better understand RA-ILD given similarities in demographics, radiology, pathology, natural history and more recently genetics.4 Looking to large, unbiased ’omic-based analyses, including proteomics, to further our understanding of RA-ILD is a logical next step. These approaches could identify novel and shared biomarkers …

View Full Text


  • Twitter @scott_matson

  • Contributors SM and JSL contributed equally to this editorial.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles